- Denifanstat for moderate‐to‐severe acne: A Phase 2, randomized, double‐blind, placebo‐controlled trial
2025-11-05
- ASC47 in Combination with Semaglutide Demonstrated Up to 111.8% Greater Relative Weight loss in Participants with Obesity Compared to Semaglutide Monotherapy
2026-05-14
- GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice
2025-11-04
- First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase Ⅲ Randomised Placebo Controlled Trial
2025-10-30
- A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity
2025-11-04
- First FASN inhibitor ASC40 to treat acne vulgaris patients: final results from a Phase 2 trial
2025-10-30
- ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity:A Ph Ib Study
2025-11-03
- ASC40， an oral once-daily fatty acid synthase (FASN) inhibitor, in patients with acne vulgaris: topline results from a phase 2 randomized, double-blind, placebo-controlled, multicenter trial
2025-10-30
- ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study
2025-10-30
- ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
2025-10-30
浙公网安备 33010802003344号 浙ICP备11050387号-1